nervous system
• levels of the endocannabinoid, 2-arachidonoyl glycerol, are decreased in the cortex, but not in the striatum, hippocampus, cerebellum, midbrain, or forebrain
|
• cultured hippocampal neurons exhibit enhanced depolarization-induced suppression of excitation and desensitize more slowly
• cultured hippocampal neurons treated with the Cnr1 (CB1R) agonist WIN55212-2 are only partially desensitized, indicating reduced agonist-mediated desensitization
|
• cultured hippocampal neurons show enhanced endocannabinoid-mediated synaptic plasticity
|
behavior/neurological
• mice show enhanced cannabinoid dependence, with mice showing more withdrawal-induced paw tremors, jumps, and diarrhea events than controls
|
• mice show enhanced antinociceptive responses to delta-9-tetrahydrocannabinol (delta9-THC), N-arachidonoyl ethanolamine anandamide (AEA) or the monoacylglycerol lipase inhibitor, JZL195, indicating enhanced sensitivity to endocannabinoids
• mice show delayed tolerance to the aninociceptive effects of delta9-THC
|
homeostasis/metabolism
• mice are more sensitive to delta-9-tetrahydrocannabinol (delta9-THC), showing enhanced antinociceptive and hypothermic responses, have delayed tolerance to delta9-THC, and show increased dependence for delta9-THC
• mice show increased responses (antinociceptive and hypothermic) to elevated levels of endogenous cannabinoids
|